drugset
drugset / Trial / NCT02044081

Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults

NCT02044081 ↗

Phase 2 Completed 60 enrolled Armata Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindPrevention

Summary

The focus of the study is to evaluate the safety of multiple study drug administrations and the study drug selectively reducing or eliminating a specific bacteria in the mouth. It will compare a liquid and gel product applied in different modes.

Timeline

Start
2014-02
Primary completion
2014-07
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject C16G2 Peptide 1.6 mg/ml Oral
Subject C16G2 Peptide 3.2 mg/ml Oral

Indications

dental caries